TheWealthWeb

ITI Pharma and Healthcare Fund Direct Growth

ITI Mutual FundEquity Scheme - Sectoral/ ThematicDirect · GrowthRisk: Very High risk3Y rank 22 of 142

NAV ₹20.5606 on 13 November 2026

AMFI name: ITI Pharma and Healthcare Fund - Direct Plan - Growth Option · Scheme code 149268 · ISIN INF00XX01BO9

1 year
+16.80%
3 years, a year
+20.53%
5 years, a year
+15.45%
Since launch, a year
+15.48%
NAV performance, last year

Returns

To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.

PeriodThis fundNIFTY HEALTHCARE INDEX TRICategory median
1M+9.38%+8.67%+5.71%
6M+12.34%+12.84%+7.79%
1Y+16.80%+38.92%+4.11%
3Y+20.53%+28.05%+14.35%
5Y+15.45%-+12.25%

Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates.

Category median: the middle return among Direct plans (Growth option) in AMFI's “Equity Scheme - Sectoral/ Thematic” category, up to 174 funds with clean data. Ranks are under “Rank among peers”.

Risk

From daily NAVs. Alpha, beta and capture are measured against NIFTY HEALTHCARE INDEX TRI.

Volatility
14.41%
Annualised, 3 years
Max drawdown
-17.07%
Worst fall from a peak, 3 years
Sharpe ratio
1.01
Return above the risk-free rate per unit of volatility, 3 years
Sortino ratio
1.37
Like Sharpe, counting only falls, 3 years
Alpha
+2.09%
Return a year beyond what beta explains, 3 years
Beta
0.58
1.00 moves in step with the benchmark, 3 years
Upside capture
59%
Share of the benchmark's rises captured, 3 years
Downside capture
96%
Share of the benchmark's falls taken (lower is better), 3 years

Every 3-year holding period

Worst
+16.24%
Median
+21.98%
Best
+28.72%
Ended positive
100.0%

Compound return a year for each 3-year window in the NAV history we hold. Less sensitive to the end date than a single 3-year figure.

Rank among peers

Direct plans, Growth option, in AMFI's “Equity Scheme - Sectoral/ Thematic” category. Each rank counts only the peers that have that figure.

Compare with Top Peers
3-Year Return RankQ1
#22of 142
+20.53%
Ahead of 120 of the other 141
Q1
Q2
Q3
Q4
1-Year Return RankQ1
#36of 233
+16.80%
Ahead of 197 of the other 232
Q1
Q2
Q3
Q4
Sharpe (Risk-Adjusted)Q1
#19of 233
1.01
Ahead of 214 of the other 232
Q1
Q2
Q3
Q4
Highest 3-year returns in the categoryDirect plans · Growth option
RankScheme Name3Y Return1Y ReturnSharpeDirect TERAUM
#1
Nippon India Mutual Fund
+46.52%+60.64%1.071.06%₹1,100 Cr
#2
HDFC Mutual Fund
+33.64%+20.34%1.070.89%₹11,128 Cr
#3
HDFC Mutual Fund
+31.28%+31.60%1.761.03%₹3,128 Cr
#4
SBI Mutual Fund
+25.42%+26.07%1.470.76%₹5,565 Cr
#5
HDFC Mutual Fund
+24.77%+10.10%1.091.10%₹1,997 Cr
#6
Mirae Asset Mutual Fund
+24.42%+27.89%1.28-₹3,458 Cr
#7
UTI Mutual Fund
+23.89%+22.00%1.311.35%₹1,399 Cr
#8
ICICI Prudential Mutual Fund
+22.73%+10.29%0.952.08%₹3,926 Cr
#22
ITI Pharma and Healthcare FundCurrent Fund
ITI Mutual Fund
+20.53%+16.80%1.010.89%₹266 Cr

Costs and fund facts

Expense ratio (stated maximum)
Direct 0.89% · Regular 2.59%
Exit load
If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL
Fund size (all plans)
₹266 CrAverage, quarter to September 2026
Benchmark
NIFTY HEALTHCARE INDEX TRI
Allotment date
8 November 2021Scheme document
Type
An open ended Equity scheme investing in Pharma and Healthcare
AMFI scheme code
149268

Fund managers (2)

  • Animesh Singh
  • Nilay Dalal

How each manager has done since taking over: fund manager scorecard.

Investment objective

The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.

From the scheme summary document filed with AMFI.

SIP calculator

A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.

Monthly SIP Amount₹10,000
Investment Horizon5 Years
Simulating monthly 1st from 15 Nov 2021 to 13 Nov 2026
Total Invested61 mos
₹6,10,000
Units: 47,134.064
Current Portfolio Value
₹9,69,105
At latest recorded NAV
Total Profit
+₹3,59,105
+58.9% absolute return
SIP XIRR
18.60%
Annualised, money-weighted
Wealth CompositionProfit is 59% of total invested capital
Invested: ₹6,10,000Profit Generated: ₹3,59,105
Same SIP in the benchmark (NIFTY HEALTHCARE INDEX TRI)Same dates & amounts
Scheme SIP Valuation
₹9,69,105
18.6% XIRR
Benchmark SIP Valuation
₹5,56,767
25.8% XIRR
Fund minus benchmark
+₹4,12,338
Over 61 monthly installments
SIP instalments are bought on the first NAV date of each month; values use the latest NAV we hold. Past returns are not a guide to future returns.

About this fund

ITI Pharma and Healthcare Fund Direct Growth is a mutual fund scheme from ITI Mutual Fund, listed by AMFI under “Equity Scheme - Sectoral/ Thematic”. This page covers the Direct plan with the Growth option. Its NAV was ₹20.5606 on 13 November 2026. It returned 16.80% over 1 year, 20.53% a year over 3 years and 15.45% a year over 5 years, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY HEALTHCARE INDEX TRI, returned 28.05% a year over 3 years. Its 3-year return ranks #22 of 142 Direct Growth plans in the same AMFI category. Q-Score: 83 out of 100, rated only against funds in the same category. The fund house rates its risk as “Very High risk” on the SEBI riskometer. Its average assets under management were ₹266 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 0.89% a year for the Direct plan. Managed by Animesh Singh and Nilay Dalal. Its scheme summary document gives the allotment date as 8 November 2021.

Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.

Plans and options of this fund (4)

PlanOptionISINAMFI codeNAV
DirectThis pageGrowthINF00XX01BO9149268₹20.5613 Nov 2026
DirectIDCWINF00XX01BQ4149271₹20.5613 Nov 2026
RegularGrowthINF00XX01BL5149270₹18.6213 Nov 2026
RegularIDCWINF00XX01BN1149269₹18.6213 Nov 2026